Scholar Rock Holding Corporation (SRRK) AI Stock Analysis

Scholar Rock Holding Corporation, based in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing therapies for severe diseases driven by protein growth factor signaling. Its pipeline includes Apitegromab, a candidate that inhibits latent myostatin activation and has completed Phase 3 clinical trials for spinal muscular atrophy. The company is also testing SRK-181 in Phase 1 trials for cancers resistant to checkpoint inhibitors. Scholar Rock collaborates with Gilead Sciences, Inc. to develop transforming growth factor beta activation inhibitors for fibrotic diseases, alongside other pipeline programs targeting neuromuscular disorders, cancer, and fibrosis.

Scholar Rock recorded $0 in revenue over the trailing twelve months ended June 30, 2026, with quarterly revenue falling 100.0% year-over-year. Historically, annual revenue rose from $379,000 in FY2016 to $33.2M in FY2022, representing a four-year revenue compound annual growth rate of 205.9%. Operating margins were negative throughout that period, standing at -404.8% in FY2022 alongside a net loss of -$131.6M and R&D expense of $124.4M. For FY2021, net income was -$131.8M on revenue of $18.8M. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $5.7M and an EPS of -$3.22.

As of June 30, 2026, Scholar Rock held $492.1M in cash and short-term investments and $203.8M in total debt, resulting in net cash of $288.3M. Total assets stood at $523.5M against shareholders' equity of $253.8M. The company maintains a current ratio of 7.02 and a debt-to-equity ratio of 0.80. In FY2025, capital expenditures were $602,000. Over a five-year period, the company's share count increased by 256.1%. Free cash flow in FY2022 was -$133.8M, driven by operating cash flow of -$132.7M.

At a closing share price of $39.90 on October 16, 2026, Scholar Rock has a market cap of $4.86B and an enterprise value of $5.78B. The stock trades at a price-to-sales multiple of 13.1x and an EV-to-revenue ratio of 8.2x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 23.9x. Over the past year, the stock returned 35.5%, outperforming the S&P 500 (SPY) return of 16.8%, but its five-year return of 46.3% trailed the index return of 83.0%.

Wall Street analysts maintain 15 Strong Buy, 2 Buy, and 1 Hold ratings on Scholar Rock, with no Sell or Strong Sell recommendations. The mean price target is $70.44, representing a 76.5% premium to the last closing price of $39.90. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $5.7M and an EPS of -$3.22. For the next fiscal year, 15 analysts project revenue of $142.2M and an EPS of -$2.58. Over the last four quarters, the company beat EPS estimates once. The next earnings date is November 13, 2026.

This page is an AI-written research summary of Scholar Rock Holding Corporation (SRRK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SRRK income statement, SRRK balance sheet, SRRK key metrics, SRRK analyst forecast, SRRK chart. See the SRRK stock overview for the latest quote and news.